STAT1 and neoplasm: TPST2 modulates the tumor immune microenvironment via tyrosine sulfation of interferon gamma receptor 1 (IFNGR1) at residue Y397, attenuating STAT1 signaling, reducing HLA expression and antigen presentation, and consequently diminishing tumor-infiltrating lymphocytes (48).